Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells

被引:7
作者
Lim, Soo-Jeong [1 ]
Choi, Hyeon Gyeom [2 ]
Jeon, Chae Kyung [3 ]
Kim, So Hee [4 ,5 ]
机构
[1] Sejong Univ, Dept Biosci & Biotechnol, Seoul, South Korea
[2] Hannam Univ, Coll Nat Sci, Taejon, South Korea
[3] Grinnell Coll, Grinnell, IA 50112 USA
[4] Ajou Univ, Coll Pharm, Suwon 443749, South Korea
[5] Ajou Univ, Res Inst Pharmaceut Sci & Technol, Suwon 443749, South Korea
基金
新加坡国家研究基金会;
关键词
MCF10AT cell lineage; paclitaxel; apoptosis; p21(Waf1/Cipl); p53; Akt; chemoresistance; HA-RAS ONCOGENE; INDUCED APOPTOSIS; SIGNALING PATHWAY; LINEAGE MODEL; RESISTANCE; TRANSFORMATION; CHEMOTHERAPY; INHIBITION; EXPRESSION; DISEASE;
D O I
10.3892/or.2015.3775
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MCF10AT cell series of human breast epithelial cancer cells includes normal MCF10A (10A), premalignant MCF10AT (10AT) and MCF10ATG3B (10ATG3B), and fully malignant MCF10CA1a (10CA1a) cells. The series is a unique model system showing progressive tumorigenic potential with the same origin. The effects of paclitaxel, a microtubule inhibitor, were evaluated in this cell system. Paclitaxel inhibited cell proliferation in a time-dependent (24, 48 and 72 h) and concentration-dependent (0-10 nM) manners with less sensitivity in 10CA1a cells. Treatment with paclitaxel (10 nM) for 24 h induced apoptosis in 10A, 10AT, 10ATG3B and 10CA1a cells, with 23.6, 26.1, 25.2 and 8.96%, respectively, in the sub-G(1) phase. Treatment with paclitaxel (0-10 nM) for 24 h, resulted in the appearance of DNA fragmentation (a hallmark of apoptosis) with less sensitivity in the 10CA1a tumor cells. Paclitaxel increased p53 protein expression in 10A, 10AT, 10ATG3B and 10CA1a cells, by 87, 102, 812 and 84%, respectively. The p21(Waf1/Cip1) protein expression increased by 2.57-, 1.53- and 2.48-fold in 10A, 10AT and 10ATG3B cells, respectively, with negligible detection in the 10CA1a cells. Activation of the Akt signaling pathway was observed in the MCF10AT cell lineage and the protein expression of phospho-Akt (Ser473 and Thr308). The downstream targets of this pathway, phospho-p70S6K and phospho-S6RP, were also inhibited by paclitaxel in 10A, 10AT and 10ATG3B cells, but minimally inhibited in 10CA1a cells, suggestive of chemoresistance in 10CA1a cells. The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage. These results collectively indicated that paclitaxel inhibited cell proliferation and induced apoptosis in the MCF10AT cell lineage, with chemoresistance in 10CA1a tumor cells. The decreased responsiveness to paclitaxel observed in 10CA1a tumor cells was likely due, in part, to activation of the Akt signaling pathway and a high expression of wild-type p53 with lack of p21(Waf1/Cip1).
引用
收藏
页码:2023 / 2030
页数:8
相关论文
共 38 条
[1]   TRANSFORMATION OF HUMAN BREAST EPITHELIAL-CELLS BY C-HA-RAS ONCOGENE [J].
BASOLO, F ;
ELLIOTT, J ;
TAIT, L ;
CHEN, XQ ;
MALONEY, T ;
RUSSO, IH ;
PAULEY, R ;
MOMIKI, S ;
CAAMANO, J ;
KLEINSZANTO, AJP ;
KOSZALKA, M ;
RUSSO, J .
MOLECULAR CARCINOGENESIS, 1991, 4 (01) :25-35
[2]   Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy [J].
Chang, F ;
Lee, JT ;
Navolanic, PM ;
Steelman, LS ;
Shelton, JG ;
Blalock, WL ;
Franklin, RA ;
McCubrey, JA .
LEUKEMIA, 2003, 17 (03) :590-603
[3]   The Akt/PKB pathway: molecular target for cancer drug discovery [J].
Cheng, JQ ;
Lindsley, CW ;
Cheng, GZ ;
Yang, H ;
Nicosia, SV .
ONCOGENE, 2005, 24 (50) :7482-7492
[4]  
Clark AS, 2002, MOL CANCER THER, V1, P707
[5]  
Dawson PJ, 1996, AM J PATHOL, V148, P313
[6]  
Dziadyk JM, 2004, ANTICANCER RES, V24, P27
[7]  
Fuchs DA, 1978, CANC TREAT REP, V62, P1819
[8]   General and recent aspects of the chemistry and structure-activity relationships of taxoids [J].
Guéritte, F .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (13) :1229-1249
[9]  
Hu LM, 2002, CANCER RES, V62, P1087
[10]   Cancer statistics, 2004 [J].
Jemal, A ;
Tiwari, RC ;
Murray, T ;
Ghafoor, A ;
Samuels, A ;
Ward, E ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29